NPM1 and acute myeloid leukemia: The aim of our study was to evaluate the impact of additional gene mutations and cytogenetic abnormalities on the outcomes of AML patients with NPM1 and/or FLT3-ITD mutations receiving intensive chemotherapy in the era of FLT3 inhibitors.